12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

BIOD-123: Completed Phase II enrollment

Biodel completed enrollment of about 130 Type I diabetics in an open-label, U.S. Phase II trial comparing BIOD-123 plus Lantus insulin glargine vs....

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >